{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:55:01Z","timestamp":1793382901694,"version":"4.5.0"},"reference-count":157,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune peripheral neuropathy primarily characterized by macrophage-mediated demyelination. Studies have identified that some patients possess autoantibodies against contactin-1 (CNTN1), neurofascin-155 (NF155), contactin-associated protein 1(Caspr1), and neurofascin-186\/140 (NF186\/140). Based on the unique pathogenesis and pathological features, the 2021 European Academy of Neurology\/Peripheral Nerve Society (EAN\/PNS) guidelines have categorized these patients separately, defining them as \u201cAutoimmune Nodopathy (AN)\u201d. The standard first-line treatments for CIDP include corticosteroids, intravenous immunoglobulin (IVIG), and plasma exchange. If these treatments are ineffective or poorly tolerated, it can be replaced with immunosuppressants or used in combination. Emerging therapeutic strategies are also being explored, among which subcutaneous injection of efgartigimod, a recently approved drug, is gradually accumulating clinical application value. The treatment strategy for AN differs from that of CIDP: Rituximab is currently regarded as the preferred option for treating AN, with corticosteroids being effective for some patients. Plasma exchange can be utilized for severe cases, while IVIG is largely ineffective for most patients with AN. Due to the low incidence of AN and the limited clinical evidence available, its treatment strategies still require large-scale clinical trials for validation. This article systematically reviews the treatment advancements for CIDP and focuses on the unique treatment strategies for AN.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1735745","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:50:36Z","timestamp":1773211836000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in the treatment of autoimmune nodopathy: based on treatment strategies of CIDP"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhi-Dan","family":"Pang","sequence":"first","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jing","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Pu","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Fan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience Center, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000000907","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy and its variants","volume":"26","author":"Gwathmey","year":"2020","journal-title":"Continuum (Minneap Minn)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx124","article-title":"Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy","volume":"140","author":"Delmont","year":"2017","journal-title":"Brain"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28239","article-title":"The difference in nerve ultrasound and motor nerve conduction studies between autoimmune nodopathy and chronic inflammatory demyelinating polyneuropathy","volume":"70","author":"Niu","year":"2024","journal-title":"Muscle Nerve"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00190-8","article-title":"Pathophysiology of chronic inflammatory demyelinating polyneuropathy: insights into classification and therapeutic strategy","volume":"9","author":"Koike","year":"2020","journal-title":"Neurol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000205","article-title":"Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg","volume":"82","author":"Querol","year":"2014","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000149","article-title":"Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins","volume":"2","author":"Querol","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04998-y","article-title":"Update on therapy of chronic immune-mediated neuropathies","volume":"43","author":"Briani","year":"2022","journal-title":"Neurol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/81.2.157","article-title":"Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone","volume":"81","author":"Austin","year":"1958","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1529-8027.2010.00245.x","article-title":"Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision","volume":"15","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.2.249","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone","volume":"62","author":"Lopate","year":"2005","journal-title":"Arch Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.4.388","article-title":"Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study","volume":"62","author":"Molenaar","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"Cd010369","DOI":"10.1002\/14651858.CD010369.pub2","article-title":"Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews","volume":"1","author":"Oaklander","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2169134","article-title":"Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.59.12_suppl_6.s33","article-title":"Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies","volume":"59","author":"Brannagan","year":"2002","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306105","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal","volume":"85","author":"Rabin","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14501","article-title":"Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"Kuitwaard","year":"2021","journal-title":"Eur J Neurol"},{"key":"B21","article-title":"Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations","volume":"2","author":"Wasserman","year":"2008","journal-title":"Patient Prefer Adherence"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12080","article-title":"Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"20","author":"Markvardsen","year":"2013","journal-title":"Eur J Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13218","article-title":"Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study","volume":"24","author":"Markvardsen","year":"2017","journal-title":"Eur J Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"van Schaik","year":"2018","journal-title":"Lancet Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S31136","article-title":"Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency","volume":"2","author":"Jolles","year":"2013","journal-title":"Immunotargets Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12573","article-title":"Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial","volume":"28","author":"Bril","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12672","article-title":"Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trial","volume":"29","author":"Hadden","year":"2024","journal-title":"J Peripher Nerv Syst"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04680513","article-title":"Principles of separation: indications and therapeutic targets for plasma exchange","volume":"9","author":"Williams","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320314","article-title":"Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment","volume":"90","author":"Lehmann","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09998-8","article-title":"Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"268","author":"Querol","year":"2021","journal-title":"J Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"Cd003906","DOI":"10.1002\/14651858.CD003906.pub4","article-title":"Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"2015","author":"Mehndiratta","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.transci.2016.01.003","article-title":"Adverse events in apheresis: An update of the WAA registry data","volume":"54","author":"M\u00f6rtzell Henriksson","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21546","article-title":"A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy","volume":"32","author":"Lieker","year":"2017","journal-title":"J Clin Apher"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9082-6","article-title":"Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients","volume":"265","author":"Dorst","year":"2018","journal-title":"J Neurol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12883-025-04294-2","article-title":"Extracorporeal therapy procedures (plasma exchange and immunoadsorption) in chronic inflammatory demyelinating polyneuropathies (CIDP)- a database analysis","volume":"25","author":"Mahlberg","year":"2025","journal-title":"BMC Neurol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8599-4","article-title":"Severe refractory CIDP: a case series of 10 patients treated with bortezomib","volume":"264","author":"Pitarokoili","year":"2017","journal-title":"J Neurol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"Cd003280","DOI":"10.1002\/14651858.CD003280.pub5","article-title":"Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"5","author":"Mahdi-Rogers","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25271","article-title":"Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy","volume":"55","author":"Kaplan","year":"2017","journal-title":"Muscle Nerve"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.51.6.1735","article-title":"Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy","volume":"51","author":"Good","year":"1998","journal-title":"Neurology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1085-9489.2005.10104.x","article-title":"High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy","volume":"10","author":"Gladstone","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.06.008","article-title":"Cyclophosphamide for treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review and meta-analysis","volume":"44","author":"Xiang","year":"2022","journal-title":"Clin Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.05.013","article-title":"Rituximab in chronic immune mediated neuropathies: a systematic review","volume":"32","author":"Chaganti","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.188912","article-title":"Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature","volume":"82","author":"Benedetti","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26804","article-title":"Rituximab in refractory chronic inflammatory demyelinating polyneuropathy","volume":"61","author":"Muley","year":"2020","journal-title":"Muscle Nerve"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae400","article-title":"Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial","volume":"148","author":"Nobile-Orazio","year":"2025","journal-title":"Brain"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14498","article-title":"Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies","volume":"27","author":"Casertano","year":"2020","journal-title":"Eur J Neurol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1177\/11795735221084837","article-title":"Recovery of chronic inflammatory demyelinating polyneuropathy on treatment with ocrelizumab in a patient with co-existing multiple sclerosis","volume":"14","author":"Auer","year":"2022","journal-title":"J Cent Nerv Syst Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000381767","article-title":"Natalizumab as a disease-modifying therapy in chronic inflammatory demyelinating polyneuropathy - A report of three cases","volume":"73","author":"Vallat","year":"2015","journal-title":"Eur Neurol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","article-title":"The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy","volume":"253","author":"Coles","year":"2006","journal-title":"J Neurol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5437-3","article-title":"Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy","volume":"257","author":"Marsh","year":"2010","journal-title":"J Neurol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.35.8.1173","article-title":"Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy","volume":"35","author":"Dyck","year":"1985","journal-title":"Neurology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03495.x","article-title":"Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis","volume":"18","author":"Cocito","year":"2011","journal-title":"Eur J Neurol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.36721\/PJPS.2023.36.4.SP.1361-1365.1","article-title":"Efficacy of azathioprine and methotrexate in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"36","author":"Mehreen","year":"2023","journal-title":"Pak J Pharm Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.177576","article-title":"Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy","volume":"81","author":"Bedi","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28436","article-title":"Mycophenolate facilitates improvement in outcome measures in treatment resistant chronic inflammatory demyelinating polyradiculoneuropathy","volume":"72","author":"Miah","year":"2025","journal-title":"Muscle Nerve"},{"key":"B63","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/wnl.53.1.57","article-title":"Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"53","author":"Hadden","year":"1999","journal-title":"Neurology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70299-0","article-title":"Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study","volume":"8","year":"2009","journal-title":"Lancet Neurol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30202-3","article-title":"Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial","volume":"17","author":"Hughes","year":"2018","journal-title":"Lancet Neurol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"Cd003280","DOI":"10.1002\/14651858.CD003280.pub4","article-title":"Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Mahdi-Rogers","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1016\/S0041-1345(98)01389-X","article-title":"Positive effects of tacrolimus in a case of CIDP","volume":"30","author":"Ahlm\u00e9n","year":"1998","journal-title":"Transplant Proc"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neurol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0679-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of bortezomib","volume":"58","author":"Tan","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25495","article-title":"POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management","volume":"94","author":"Dispenzieri","year":"2019","journal-title":"Am J Hematol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421999631","article-title":"Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study","volume":"14","author":"Motte","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"B73","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2018.08.004","article-title":"Kill \u2018Em all: efgartigimod immunotherapy for autoimmune diseases","volume":"39","author":"Bayry","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1533167","article-title":"Short-term treatment of CIDP with efgartigimod: a case series in China","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-333112","article-title":"Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study","volume":"95","author":"Querol","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13019","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers","volume":"14","author":"Yap","year":"2021","journal-title":"Clin Transl Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic effects of batoclimab in chinese patients with generalized myasthenia gravis: A double-blinded, randomized, placebo-controlled phase II study","volume":"11","author":"Yan","year":"2022","journal-title":"Neurol Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235983","article-title":"Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B85","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","article-title":"Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri","year":"2025","journal-title":"Rheumatol Int"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlife.2024.05.005","article-title":"BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy","volume":"2","author":"Zhang","year":"2024","journal-title":"hLife"},{"key":"B87","doi-asserted-by":"publisher","first-page":"100704","DOI":"10.1016\/j.medj.2025.100704","article-title":"Anti-BCMA CAR-T cell therapy in relapsed\/refractory chronic inflammatory demyelinating polyneuropathy","volume":"6","author":"Dong","year":"2025","journal-title":"Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00199-1","article-title":"CD19-targeted CAR T-cell therapy for treatment-refractory autoimmune neuropathies","volume":"24","author":"Motte","year":"2025","journal-title":"Lancet Neurol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.251","article-title":"SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking","volume":"50","author":"Alexander","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.1.127","article-title":"Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy","volume":"72","author":"Vermeulen","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10010-6","article-title":"Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"267","author":"Burt","year":"2020","journal-title":"J Neurol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15857","article-title":"Efficacy of hematopoietic stem cell transplantation treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"30","author":"Zheng","year":"2023","journal-title":"Eur J Neurol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.38363","article-title":"Progress in hematopoietic stem cell transplantation for CIDP","volume":"17","author":"Qin","year":"2020","journal-title":"Int J Med Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01221-y","article-title":"The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-targeted therapies","volume":"19","author":"Querol","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.331","article-title":"Terminal complement activation is increased and associated with disease severity in CIDP","volume":"3","author":"Quast","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"116509","DOI":"10.1016\/j.jns.2019.116509","article-title":"Complement deposition and macrophage-induced demyelination in CIDP with anti-LM1 antibodies","volume":"408","author":"Koike","year":"2020","journal-title":"J Neurol Sci"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy134","article-title":"Subacute nodopathy with conduction blocks and anti-neurofascin 140\/186 antibodies: an ultrastructural study","volume":"141","author":"Vallat","year":"2018","journal-title":"Brain"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12551","article-title":"An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy","volume":"28","author":"Querol","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2019.09.004","article-title":"Eculizumab and beyond: the past, present, and future of complement therapeutics","volume":"33","author":"Patriquin","year":"2019","journal-title":"Transfus Med Rev"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: A review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01297-w","article-title":"Eculizumab: A review in neuromyelitis optica spectrum disorder","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"B103","doi-asserted-by":"publisher","first-page":"Cd008630","DOI":"10.1002\/14651858.CD008630.pub5","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr\u00e9 syndrome","volume":"1","author":"Doets","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2423002","article-title":"An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder","volume":"24","author":"Balaban","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"B105","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/jnnp-2024-334165","article-title":"Novel therapies in CIDP","volume":"96","author":"Mair","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B106","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/82_2015_478","article-title":"BTK signaling in B cell differentiation and autoimmunity","volume":"393","author":"Corneth","year":"2016","journal-title":"Curr Top Microbiol Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2023.04.001","article-title":"Novel agents in waldenstr\u00f6m macroglobulinemia","volume":"37","author":"Sarosiek","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim","year":"2021","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000720","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy","volume":"7","author":"Castellani","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2023.0127","article-title":"Therapeutic outcomes and electrophysiological biomarkers in anti-myelin-associated glycoprotein neuropathy: A multicenter cohort study in South Korea","volume":"20","author":"Min","year":"2024","journal-title":"J Clin Neurol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jneuroim.2013.01.001","article-title":"Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - a new mechanism of action","volume":"256","author":"Bick","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-025-01133-3","article-title":"The changing landscape of primary autoimmune neuropathies","volume":"21","author":"Caballero-\u00c1vila","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12237","article-title":"ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components","volume":"22","author":"Illa","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv054","article-title":"Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia","volume":"138","author":"Miura","year":"2015","journal-title":"Brain"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27142","article-title":"Long-term follow up in anti-contactin-1 autoimmune nodopathy","volume":"97","author":"Caballero-\u00c1vila","year":"2025","journal-title":"Ann Neurol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002418","article-title":"Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy","volume":"86","author":"Devaux","year":"2016","journal-title":"Neurology"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.528489","article-title":"Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies","volume":"289","author":"Labasque","year":"2014","journal-title":"J Biol Chem"},{"key":"B119","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.expneurol.2016.10.006","article-title":"Complement deposition induced by binding of anti-contactin-1 auto-antibodies is modified by immunoglobulins","volume":"287","author":"Appeltshauser","year":"2017","journal-title":"Exp Neurol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004773","article-title":"Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies","volume":"90","author":"Burnor","year":"2018","journal-title":"Neurology"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac418","article-title":"Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage","volume":"146","author":"Appeltshauser","year":"2023","journal-title":"Brain"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.986018","article-title":"Case report: Immunoadsorption therapy for anti-caspr1 antibody-associated nodopathy","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10646-y","article-title":"Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis","volume":"269","author":"Hu","year":"2022","journal-title":"J Neurol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001098","article-title":"Clinical and laboratory features in anti-NF155 autoimmune nodopathy","volume":"9","author":"Mart\u00edn-Aguilar","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.939062","article-title":"Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"578420","DOI":"10.1016\/j.jneuroim.2024.578420","article-title":"Anti-contactin-associated protein 1 antibody-positive nodopathy presenting with central nervous system symptoms","volume":"394","author":"Mori","year":"2024","journal-title":"J Neuroimmunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.03.010","article-title":"Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects","volume":"76","author":"Renaudineau","year":"2009","journal-title":"Joint Bone Spine"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112140-20240228-00130","article-title":"Clinical features of anti-neurofascin-155 antibody positive autoimmune nodopathy in 6 children","volume":"62","author":"Fang","year":"2024","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.04.007","article-title":"Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour","volume":"377","author":"Wang","year":"2017","journal-title":"J Neurol Sci"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11759-2","article-title":"Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study","volume":"270","author":"Liu","year":"2023","journal-title":"J Neurol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"578326","DOI":"10.1016\/j.jneuroim.2024.578326","article-title":"Low-dose rituximab treatment in a patient with anti-neurofascin-155 IgG4 autoimmune nodopathy","volume":"389","author":"Kmezic","year":"2024","journal-title":"J Neuroimmunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200295","article-title":"Different patterns of autoantibody secretion by peripheral blood mononuclear cells in autoimmune nodopathies","volume":"11","author":"Rohrbacher","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.602102","article-title":"Case report: daratumumab in a patient with severe refractory anti-NMDA receptor encephalitis","volume":"11","author":"Ratuszny","year":"2020","journal-title":"Front Neurol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09585-6","article-title":"Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis","volume":"267","author":"Scheibe","year":"2020","journal-title":"J Neurol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15266","article-title":"Daratumumab for treatment-refractory antibody-mediated diseases in neurology","volume":"29","author":"Scheibe","year":"2022","journal-title":"Eur J Neurol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12465","article-title":"Report of a fulminant anti-pan-neurofascin-associated neuropathy responsive to rituximab and bortezomib","volume":"26","author":"Fels","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S6840","article-title":"Ofatumumab: a novel monoclonal anti-CD20 antibody","volume":"3","author":"Lin","year":"2010","journal-title":"Pharmgenomics Pers Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of anti-B cell therapeutics in autoimmune neurological diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01222-x","article-title":"Therapeutic monoclonal antibody therapies in chronic autoimmune demyelinating neuropathies","volume":"19","author":"Briani","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12679","article-title":"Ofatumumab for treating autoimmune nodopathy","volume":"30","author":"Hu","year":"2025","journal-title":"J Peripher Nerv Syst"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: first approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00593-7","article-title":"Efficacy and safety of inebilizumab in igG4-related disease: protocol for a randomized controlled trial","volume":"10","author":"Perugino","year":"2023","journal-title":"Rheumatol Ther"},{"key":"B148","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1279808","article-title":"Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies","volume":"14","author":"Ren","year":"2023","journal-title":"Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12896","article-title":"Devastating humoral CIDP variant remitted by autologous stem cell transplantation","volume":"23","author":"Scheibe","year":"2016","journal-title":"Eur J Neurol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12610","article-title":"Successful autologous hematopoietic stem cell transplantation in a refractory anti-Caspr1 antibody nodopathy","volume":"29","author":"Afanasiev","year":"2024","journal-title":"J Peripher Nerv Syst"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70124","article-title":"A comparative real-world study evaluating the safety of immune globulin infusion (Human) 10% Solution and other intravenous immunoglobulin therapies for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"34","author":"Layton","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70269","article-title":"Preliminary observations on the efficacy of efgartigimod therapy in autoimmune nodopathy","volume":"32","author":"Tai","year":"2025","journal-title":"Eur J Neurol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000603","article-title":"Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy","volume":"6","author":"Stengel","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.4103\/NRR.NRR-D-24-01363","article-title":"Regulatory T cells in neurological disorders and tissue regeneration: Mechanisms of action and therapeutic potentials","volume":"21","author":"Jie","year":"2026","journal-title":"Neural Regener Res"},{"key":"B156","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/jnnp-2016-315480","article-title":"Nodes, paranodes and neuropathies","volume":"89","author":"Fehmi","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B157","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/WCO.0000000000001195","article-title":"Pan-Neurofascin autoimmune nodopathy - a life-threatening, but reversible neuropathy","volume":"36","author":"Appeltshauser","year":"2023","journal-title":"Curr Opin Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735745\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:50:38Z","timestamp":1773211838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735745\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":157,"alternative-id":["10.3389\/fimmu.2026.1735745"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1735745","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"article-number":"1735745"}}